U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H12N8O4S3
Molecular Weight 440.481
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFTEZOLE

SMILES

[H][C@]12SCC(CSC3=NN=CS3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O

InChI

InChIKey=DZMVCVMFETWNIU-LDYMZIIASA-N
InChI=1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description is created based on several sources, including http://aksci.com/item_detail.php?cat=H709 and http://www.ncbi.nlm.nih.gov/pubmed/994325

Ceftezole sodium is a cephalosporin antibiotic. Ceftezole was found to be a broad-spectrum antibiotic, active in vitro against many species of gram-positive and gram-negative bacteria except Pseudomonas aeruginosa, Serratia marcescens and Proteus vulgaris. Ceftezole sodium is used as an injectable or through an intravenous mode of delivery. The bactericidal activity of ceftezole results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). The PBPs are transpeptidases which are vital in peptidoglycan biosynthesis. Therefore, their inhibition prevents this vital cell wall component from being properly synthesized. Ceftezole has been shown to exhibit potent alpha-glucosidase inhibitory activity. In in vitro alpha-glucosidase assays, ceftezole was shown to be a reversible, non-competitive inhibitor of yeast alpha-glucosidase with a Ki value of 5.78 x 10(-7) M when the enzyme mixture was pretreated with ceftezole. Ceftezole is used for the treatment of susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, endocarditis. Surgical prophylaxis.

Originator

Curator's Comment: Ceftezole sodium injection is a first-generation cephalosporin, developed by the Japanese company Fujisawa

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
Curative
Ceftezole sodium for injection

Approved Use

Indicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

IM 2-4 g/day in 2-3 divided doses.
Route of Administration: Intramuscular
In Vitro Use Guide
Susceptibilities of 48 clinical isolates of S. aureus to ceftezole showed a peak at 0.20 ug/ml and no resistant strain with an MIC of 3.13 ug/ml or above was observed.
Name Type Language
CEFTEZOLE
INN   MI   WHO-DD  
INN  
Official Name English
CEFTEZOLE [MI]
Common Name English
Ceftezole [WHO-DD]
Common Name English
J01DB12
Code English
(6R,7R)-8-OXO-7-(2-(1H-TETRAZOL-1-YL)ACETAMIDO)-3-((1,3,4-THIADIAZOL-2-YLTHIO)METHYL)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
ceftezole [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ01DB12
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
WHO-ATC J01DB12
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
NCI_THESAURUS C357
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID0022771
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
DRUG BANK
DB13821
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
NCI_THESAURUS
C76038
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
DRUG CENTRAL
561
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
ChEMBL
CHEMBL1697829
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
FDA UNII
2Z86SYP11W
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
MESH
C012811
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
CAS
26973-24-0
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
WIKIPEDIA
CEFTEZOLE
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
MERCK INDEX
m1061
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY Merck Index
SMS_ID
100000081853
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
CHEBI
135716
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
EVMPD
SUB07424MIG
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
INN
3914
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY
PUBCHEM
65755
Created by admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
PRIMARY